Newark U.S. attorney's office has closed an investigation on Schering's Puerto Rico manufacturing facility. The inquiry, which was announced in May 2002, focused on the use of unapproved raw materials (1"The Pink Sheet" May 20, 2002, In Brief)...

FDA/Justice Department investigation of Schering-Plough's GMP compliance at its Manati, P.R. facility is focusing on ribavirin, among other products, firm discloses. The investigation itself was disclosed in May; Schering has not previously identified specific products targeted (1"The Pink Sheet" June 24, 2002, In Brief)...

Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17